Processa PharmaceuticalsPCSA
13F holders, Q2 2026 (June 30)12holders +2
4new positions
2sold out
1famous investor
$1.95avg. 13F price*
At the end of Q2 2026, 12 institutions reported holding Processa Pharmaceuticals Inc. (PCSA) in their 13F filings, up 2 from Q1 2026. 4 opened new positions and 2 sold out. The largest holders were Connective Capital Management, LLC ($164K), Stonepine Capital Management, LLC ($106K) and Geode Capital Management, LLC ($42K). One famous investor held it Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Processa Pharmaceuticals Inc.
- CUSIP
- 74275C403
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2026 → Q2 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 4 | $122K |
| Exits | 2 | $50 |
All 13F filers, Q1 2026 → Q2 2026: 80,681 shares bought and 2,838 shares sold, net +77,843 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 12 holders
| Connective Capital Management, LLC | 0.12% | Add +20.6% | 85,274 | $164K |
| Stonepine Capital Management, LLC | 0.08% | No change | 55,000 | $106K |
| Geode Capital Management, LLC | 0.00% | Reduce -11.3% | 22,090 | $42K |
| Citadel Advisors | 0.00% | New | 21,306 | $41K |
| StoneX Group Inc. | 0.00% | New | 11,437 | $30K |
| XTX Topco Ltd | 0.00% | New | 13,292 | $26K |
| Jane Street Group, LLC | 0.00% | New | 13,264 | $25K |
| Vanguard Capital Management LLC | 0.00% | No change | 12,729 | $24K |
| Vanguard Fiduciary Trust Co. | 0.00% | No change | 10,857 | $21K |
| UBS Group AG | 0.00% | Add +207.9% | 7,794 | $15K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +172.2% | 2,499 | $5K |
| Jones Financial Companies LLLP | 0.00% | No change | 7 | $13 |
"% of holder's portfolio" is PCSA's weight in each manager's 13F, not the share of Processa Pharmaceuticals Inc. the manager owns.